RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma
Rong Yu, Wenqing Wang, Tao Li, Jiancheng Li, Kuaile Zhao, Weihu Wang, Long Liang, Haishan Wu, Tashan Ai, Wei Huang, Liyun Li, Wentao Yu, Chenlu Wei, Yidi Wang, Wei Shen, Zefen Xiao, Rong Yu, Wenqing Wang, Tao Li, Jiancheng Li, Kuaile Zhao, Weihu Wang, Long Liang, Haishan Wu, Tashan Ai, Wei Huang, Liyun Li, Wentao Yu, Chenlu Wei, Yidi Wang, Wei Shen, Zefen Xiao
Abstract
Definitive chemoradiotherapy is the standard of care for inoperable locoregionally advanced esophageal squamous cell carcinoma (ESCC). Immune checkpoint inhibitors such as anti-PD-1/PD-L1 antibodies have led to a paradigm shift in advanced, metastatic ESCC treatment; however, the effect of incorporating checkpoint inhibitors in the definitive management of ESCC is unclear. Tislelizumab is an anti-PD-1 antibody specifically engineered to minimize FcɣR binding on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. The RATIONALE 311 study described here (BGB-A317-311; NCT03957590) is a registrational multicenter, double-blind, placebo-controlled, randomized, Phase III clinical trial designed to evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in patients with inoperable localized ESCC.
Keywords: Phase III clinical trial; concurrent chemoradiotherapy; esophageal squamous cell carcinoma; immune checkpoint inhibitor; immunotherapy; programmed cell death-1 (PD-1); tislelizumab.
Source: PubMed